About us

Since 1994 we have provided screening libraries of lead-like molecules, macrocycles and fragments as well as research reagents and building blocks that have greatly enhanced the medicinal chemistry programs of our clients throughout the world.

With our R&D sites in Winston-Salem, NC and Moscow, Russia we can respond efficiently to the demands of our industrial and academic partners through collaborative engagement in many disciplines:

  • Medicinal chemistry: hit identification, hit-to-lead, lead optimization, fragment based drug design (FBDD), structure based drug design (SBDD), parallel chemistry & purification
  • Biology: assay validation, HTS, high content screening, cellular biology, ADMET and PK
  • Compound collection management

Leveraging 20+ years of research experience, we have refined our powerful Compound-to-Target™  platform that facilitates the discovery of novel modulators of pharmacologically-relevant “difficult” targets and signaling pathways:

  • Protein-Protein interactions
  • WNT/ β-catenin
  • Apoptosis
  • Infectious diseases

Our technology is based on innovative chemistry enabling the creation of novel lead-like molecules and macrocycles supported by experimental biological testing to refine the design via synchronized target-based and phenotypic screening cascades. The platform provides valuable deliverables in the areas of oncology and infectious disease.

Please contact us to learn more about ASINEX’s products and discovery programs